Minerva Neurosciences (NERV) Net Cash Flow (2013 - 2026)

Minerva Neurosciences has reported Net Cash Flow for 14 years, with the latest figure at -$49.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1118.45% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (up 187.84% YoY), and the FY2025 full-year result was $60.9 million, up 411.7% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$49.6 million, down from $70.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $70.0 million in Q4 2025, with the low at -$49.6 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$1.7 million across 5 years, with a median of -$4.4 million in 2024.
• Annual changes were most pronounced in 2024 — Net Cash Flow slumped 5180.68% — and 2025, when it soared 1454.52%.
• Minerva Neurosciences' Net Cash Flow stood at -$4.1 million in 2022, then tumbled by 45.2% to -$6.0 million in 2023, then grew by 13.76% to -$5.2 million in 2024, then soared by 1454.52% to $70.0 million in 2025, then sank by 170.89% to -$49.6 million in 2026.
• The last three Net Cash Flow figures came in at -$49.6 million (Q1 2026), $70.0 million (Q4 2025), and -$2.9 million (Q3 2025), per Business Quant data.